nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2020-7-3-70-77nodgo-627Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSДиагностика и лечение посттрансфузионной перегрузки железом в детской гематологии: обзор литературыDiagnosis and treatment of post-transfusion iron overload in pediatric hematology: literature reviewhttps://orcid.org/0000-0002-3005-2085БатмановаН. А.BatmanovaN. A.

Наталья Андреевна Батманова, кандидат медицинских наук, врач-детский онколог детского отделения химиотерапии гемобластозов отдела гематологии и трансплантации костного мозга

115478, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Pediatric Oncologist of the Children’s Department of Hemoblastosis Chemotherapy of the Department of Hematology and Bone Marrow Transplantation

23 Kashirskoe shosse, Moscow, 115478

batmanova_nataly@mail.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Доктор медицинских наук, заведующий детским отделением химиотерапии гемобластозов отдела гематологии и трансплантации костного мозга

115478, Москва, Каширское шоссе, 23

Dr. of Sci. (Med.), Head of the Children’s Department of Hemoblastosis Chemotherapy of the Department of Hematology and Bone Marrow Transplantation

23 Kashirskoe shosse, Moscow, 115478

timurvaliev@mail.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

Кандидат медицинских наук, заместитель директора по научной и образовательной работе НИИ детской онкологии и гематологии

115478, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work of Research Institute of Pediatric Oncology and Hematology 

23 Kashirskoe shosse, Moscow, 115478

 

k.kirgizov@ronc.ruhttps://orcid.org/0000-0001-6131-1783ВарфоломееваС. Р.VarfolomeevaS. R.

Доктор медицинских наук, профессор, заместитель директора по научной и лечебной работе – директор НИИ детской онкологии и гематологии аппарата управления

115478, Москва, Каширское шоссе, 23

Dr. of Sci. (Med.), Professor, Deputy Director for Research and Clinical Work – Director of the Research Institute of Pediatric Oncology and Hematology

23 Kashirskoe shosse, Moscow, 115478

s.varfolomeeva@ronc.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian Federation202020092020737077Copyright © Батманова Н.А., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р., 20202020Батманова Н.А., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р.Batmanova N.A., Valiev T.T., Kirgizov K.I., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/627

Трансфузии эритроцитной массы/взвеси входят в современные стандарты сопроводительной терапии анемического синдрома при доброкачественных и злокачественных заболеваниях системы крови как у взрослых, так и у детей. Особенности метаболизма железа в организме человека при трансфузиях эритроцитсодержащих сред приводят к его повышенному накоплению в органах и тканях с развитием посттрансфузионной перегрузки железом. Клинические проявления данного состояния различны по степени тяжести, но при отсутствии хелаторной терапии могут привести к жизнеугрожающим осложнениям. В обзоре литературы описаны основные причины перегрузки железом, клинические проявления, а также диагностика и лечение избыточного накопления железа в организме.

Packed red blood cells are important part of modern treatment recommendations of anemic syndrome in benign and malignant diseases of hematopoietic system in both adults and children. Special features of iron metabolism in the human body after erythrocytes-containing transfusions lead to its increased accumulation in organs and tissues and post-transfusion iron overload development. Clinical manifestation of post-transfusion iron overload varies, but in the absence of chelation therapy can lead to life-threatening complications. This literature review describes the main causes of iron overload, clinical features, and diagnosis and treatment of iron overload.

перегрузка железомхелаторная терапиядеферазироксмиелодиспластический синдромнаследственные гемохроматозыiron overloadchelation therapydeferasiroxmyelodysplastic syndromehereditary hemochromatosisReferencesSlonim A.D., Joseph J., Turenne W., Sharangpani A., Luban N.L.C. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008:48(1):73–80. doi: 10.1111/j.1537-2995.2007.01484.Slonim A.D., Joseph J., Turenne W., Sharangpani A., Luban N.L.C. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008:48(1):73–80. doi: 10.1111/j.1537-2995.2007.01484.Bercovitz S., Josephson C. Transfusion considerations in pediatric hematology and oncology. Hematol Oncol Clin North America 2019;33(5):903–13. doi: 10.1016/j.hoc.2019.05.011.Bercovitz S., Josephson C. Transfusion considerations in pediatric hematology and oncology. Hematol Oncol Clin North America 2019;33(5):903–13. doi: 10.1016/j.hoc.2019.05.011.Gauvin F., Champagne M., Robillard P. Long-term survival rate of pediatric patients after blood transfusions. Transfusion 2008;48(5):801–8. doi: 10.1111/j.1537-2995.2007.01614.Gauvin F., Champagne M., Robillard P. Long-term survival rate of pediatric patients after blood transfusions. Transfusion 2008;48(5):801–8. doi: 10.1111/j.1537-2995.2007.01614.Jang J.H., Lee J.-H., Yoon S.-S., Jo D.-Y., Kim H.-J., Chung J., Lee J.W. Korean guidline for iron chelator therapy in transfusion-indused iron overload. J Korean Med Sci 2013;28:1563–72. doi:10.3346/jkms2013.28.11.1563.Jang J.H., Lee J.-H., Yoon S.-S., Jo D.-Y., Kim H.-J., Chung J., Lee J.W. Korean guidline for iron chelator therapy in transfusion-indused iron overload. J Korean Med Sci 2013;28:1563–72. doi:10.3346/jkms2013.28.11.1563.Wrighting D., Andrews N. Iron homeostasis and erythropoiesis. Curr Top Dev Biol 2008;82:141–67. doi: 10.1016/S0070-2153(07)00006-3.Wrighting D., Andrews N. Iron homeostasis and erythropoiesis. Curr Top Dev Biol 2008;82:141–67. doi: 10.1016/S0070-2153(07)00006-3.Brissot E., Bernard D., Loreal O., Brissot P., Troadec M.-B. Too much iron: a mask foe for leukemias. Blood Rev 2020;39:100617. doi: 10.1016/j.blre.2019.100617.Brissot E., Bernard D., Loreal O., Brissot P., Troadec M.-B. Too much iron: a mask foe for leukemias. Blood Rev 2020;39:100617. doi: 10.1016/j.blre.2019.100617.Som D., Jodie B.L. Overview of iron metabolism in health and disease. Hemodial Int 2017;21(Suppl 1):6–20. doi: 10.1111/hdi.12542.Som D., Jodie B.L. Overview of iron metabolism in health and disease. Hemodial Int 2017;21(Suppl 1):6–20. doi: 10.1111/hdi.12542.Савченко В.Г., Абдулкадыров К.М., Масчан А.А., Сметанина Н.С., Голенков А.К., Кохно А.В., Сысоева Е.П., Савинова М.Т., Шелехова Т.В., Финогенова Н.А., Зубаровская Л.С., Капланов К.Д., Кравченко Е.Г., Лопатина Е.Г. Открытое многоцентровое исследование деферазирокса в лечении посттрансфузионной перегрузки железом у больных миелодиспластическими синдромами, талассемией и другими формами анемий. Гематология и трансфузиология 2015;60(4):7–14.Savchenko V.G., Abdulkadyrov K.M., Maschan A.A., Smetanina N.S., Golenkov A.K., Kokhno A.V., Sysoeva E.P., Savinova M.T., Shelehova T.V., Finogenova N.A., Zubarovskayya L.S., Kaplanov K.D., Kravchenko E.G., Lopatina E.G. Open multi-center trial evaluating the efficacy of deferasirox therapy for posttransfusion iron overload in patients with myelodysplastic syndromes, thalassemia and other anemias. Gematologiya i transfuziologiya = Hematology and Transfusiology 2015;60(4):7–14. (In Russ.).List A.F. Iron overload in myelodysplastic syndromes. Diagnosis and management. Cancer control 2010;17 Suppl:2–8. doi: 10.1177/107327481001701s01.List A.F. Iron overload in myelodysplastic syndromes. Diagnosis and management. Cancer control 2010;17 Suppl:2–8. doi: 10.1177/107327481001701s01.Siddique A., Kowdley K.V. Review article: the iron overload syndromes. Aliment Pharmacol Ther 2012;35(8):876–93. doi: 10.1111/j.1365-2036.2012.05051.Siddique A., Kowdley K.V. Review article: the iron overload syndromes. Aliment Pharmacol Ther 2012;35(8):876–93. doi: 10.1111/j.1365-2036.2012.05051.Циммерман Я.С. Первичный (наследственный) гемохроматоз. Клиническая медицина 2017;95(6);513–8. doi: 0.18821/0023-21492017-95-6-513-518.Tzimmerman Ya.S. Primary (Hereditary) hemochromatosis. Klinicheskaya meditsina = Clinical Medicine 2017;96(6):513–8. (In Russ.). doi: 0.18821/0023-21492017-95-6-513-518.Emy P.Y., Levin T.L., Sheth S.S., Ruzal-Shapiro C., Garvin J., Berdon W.E. Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. Am J Roentgenol 1997;168:1011–5. doi: 10.2214/ajr.168.4.9124106.Emy P.Y., Levin T.L., Sheth S.S., Ruzal-Shapiro C., Garvin J., Berdon W.E. Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. Am J Roentgenol 1997;168:1011–5. doi: 10.2214/ajr.168.4.9124106.Shan J., Kurtin E.S., Arnold L., Lindroos-Kolqvist P., Tinsley S. Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clin J Oncol Nursing 2012;16 Suppl:37–46. doi:10.1188/12.CJON.S1.37-46.Shan J., Kurtin E.S., Arnold L., Lindroos-Kolqvist P., Tinsley S. Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clin J Oncol Nursing 2012;16 Suppl:37–46. doi:10.1188/12.CJON.S1.37-46.Gattermann N. Overview in guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24–9. doi: 10.1007/s12185-008-0118-z.Gattermann N. Overview in guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24–9. doi: 10.1007/s12185-008-0118-z.Kushner J.P., Porter J.P., Olivieri N.F. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47–61. doi: 10.1182/asheducation-2001.1.47.Kushner J.P., Porter J.P., Olivieri N.F. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47–61. doi: 10.1182/asheducation-2001.1.47.Coates T., Wood J. How we manage iron overload in sickle cell patients. Br J Haematol 2017;177(5):703–16. doi: 10.1111/bjh.14575.Coates T., Wood J. How we manage iron overload in sickle cell patients. Br J Haematol 2017;177(5):703–16. doi: 10.1111/bjh.14575.Brissot P., Troadec M.-B., Loreal O., Brissot E. Pathophysiology and classification of iron overload diseases. Transfus Clin Biol 2019;26(1):80–8. doi: 10.1016/j.tracli.2018.08.006.Brissot P., Troadec M.-B., Loreal O., Brissot E. Pathophysiology and classification of iron overload diseases. Transfus Clin Biol 2019;26(1):80–8. doi: 10.1016/j.tracli.2018.08.006.Trinder D., Fox C., Vautier G., Olynyk J.K. Molecular pathogenesis of iron overload. GUT 2002;51(2):290–5. doi: 10.1136/gut.51.2.290.Trinder D., Fox C., Vautier G., Olynyk J.K. Molecular pathogenesis of iron overload. GUT 2002;51(2):290–5. doi: 10.1136/gut.51.2.290.Delea E.T., Edelsberg J., Sofrygin O., Thomas S.K., Baladi J.F., Phatak P.D., Coates T.D. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-depending thalassemia: a literature review. Transfusion 2007;47(10):1919–29. doi: 10.1111/j.1537-2995.2007.01416.x.Delea E.T., Edelsberg J., Sofrygin O., Thomas S.K., Baladi J.F., Phatak P.D., Coates T.D. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-depending thalassemia: a literature review. Transfusion 2007;47(10):1919–29. doi: 10.1111/j.1537-2995.2007.01416.x.Baran E.J. Chelation therapies: a chemical and biochemical perspective. Curr Med Chem 2010;17(31):3658–72. doi: 10.2174/092986710793213760.Baran E.J. Chelation therapies: a chemical and biochemical perspective. Curr Med Chem 2010;17(31):3658–72. doi: 10.2174/092986710793213760.Goldberg K.E., Neogi S., Lal A., Higa A., Fung E. Nutritional deficiencies are common in patients with transfusion-dependent thalassemia and associated with iron overload. J Food Nutr Research 2018;6(10):674–81. doi:10.12691/jfnr-6-10-9.Goldberg K.E., Neogi S., Lal A., Higa A., Fung E. Nutritional deficiencies are common in patients with transfusion-dependent thalassemia and associated with iron overload. J Food Nutr Research 2018;6(10):674–81. doi:10.12691/jfnr-6-10-9.Bollig C., Schell L.K., Rucker G., Allert R., Motschall E., Niemeyer C.M., Bassler D., Meerpohl J.J. Deferazirox for managing irin overload in people with thalassemia. Cochrane Database Syst Rev 2017;2017(8):CD007476. doi: 10.1002/14651858.CD007476.pub3.Bollig C., Schell L.K., Rucker G., Allert R., Motschall E., Niemeyer C.M., Bassler D., Meerpohl J.J. Deferazirox for managing irin overload in people with thalassemia. Cochrane Database Syst Rev 2017;2017(8):CD007476. doi: 10.1002/14651858.CD007476.pub3.Messa E., Ciloni D., Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv Hematol 2010;2010:756289. doi: 10.1155/2010/756289.Messa E., Ciloni D., Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv Hematol 2010;2010:756289. doi: 10.1155/2010/756289.Kontoghiorghe C.N., Kontoghiorghes G.J. Efficacy and safety of ironchelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Therapy 2016;10:465–81. doi: 10.2147/DDDT.S79458.Kontoghiorghe C.N., Kontoghiorghes G.J. Efficacy and safety of ironchelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Therapy 2016;10:465–81. doi: 10.2147/DDDT.S79458.Leitch A.H., Gatterman N. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Crit Rev Oncol Hematol 2019;141:54–72. doi: 10.1016/j.critrevonc.2019.06.002.Leitch A.H., Gatterman N. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. Crit Rev Oncol Hematol 2019;141:54–72. doi: 10.1016/j.critrevonc.2019.06.002.

The authors declare that there are no conflicts of interest present.